#SVML Sovereign Metals Ltd – Issue of Unlisted Performance Rights

Sovereign Metals Limited (Sovereign or the Company) (ASX:SVM, AIM:SVML) advises that it has issued 1,560,000 Performance Rights to key employees and consultants as follows: ·      740,000 performance rights subject to the “Pre-Feasibility Study Milestone” expiring on 30 September 2023; and ·      820,000 performance rights subject to the “Feasibility Study Mine Milestone” expiring on 31 October […]

#TEK Tekcapital PLC – Investee Company MicroSalt Partners with Hannaford Brothers

  Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that Hannaford Brothers one of the most respected food retailers in the north-eastern United States has agreed to stock both sizes of MicroSalt’s new table-top shakers.     MicroSalt® provides […]

#TEK TEKCAPITAL PLC – NOMAD and Broker appointed for MicroSalt AIM IPO

Portfolio Company Update: MicroSalt, Ltd. (“MicroSalt”) Appointment of Nominated Adviser and Broker for Proposed AIM IPO   Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that Zeus Capital Limited (“Zeus”) has been appointed by portfolio company MicroSalt as […]

#HVO hVIVO plc – Investors’ Chronicle

Building on decades of experience, hVIVO is currently the only CRO focused on challenge studies, providing world class expertise and capabilities in challenge agent manufacture, a unique portfolio of established human challenge models to test a broad range of infectious and respiratory disease products, and specialist drug development and clinical consultancy services through its Venn Life Sciences subsidiary. hVIVO contract awards Since the release of interim results in early September, hVIVO has announced a massive £13.4mn contract with a US biotechnology client, a repeat customer, to test its respiratory syncytial virus antiviral candidate using hVIVO’s established RSV Human Challenge Study Model. Although difficult to assess the challenge study market, Liberum Capital estimates there are around 20 challenge studies conducted each year. Using the prevailing average contract size of £6.7mn, this indicates £100mn-£135mn of challenge study work each year, excluding any additional income through manufacturing and validating bespoke challenge agent. Around 60 per cent of hVIVO’s current order book relates to biotech customers and the balance relates to big pharma, with the group carrying out three active challenge studies for big pharma in the first half of 2022 and two full-service challenge studies with values exceeding £25mn. Moreover, hVIVO has signed up eight challenge studies with big pharma companies since 2018, 12  and all the big pharma clients are repeat customers. Improving financials Backed by a bumper order book and having booked £9mn of group revenue in July and August 2022, house broker FinnCap expects the group’s hVIVO division, which carries out the challenge studies, to grow revenue from £29.4mn last year to £42.5mn in 2022 and account for 82 per cent of its total revenue estimate of £51.1mn. Furthermore, taking account of challenge study contract wins, revenue from Venn Life, laboratory services and non-challenge studies, the brokerage estimates that £53mn of its 2023 revenue estimate of £56mn is already covered. SGS’s expertise is in performing influenza challenge studies, but it also has Malaria challenge, and RSV challenge models.

#TEK Tekcapital Plc – Appointment to the Board of MicroSalt

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products that can improve people’s lives, is pleased to announce that Judith Batchelar OBE has joined the board of MicroSalt.     Judith currently serves as Deputy Chair of the U.K. Environment Agency, sits on UK Research and Innovation’s […]

#KAV Kavango Resources Plc- Strategic Financing to raise £3million

Kavango Resources plc (LSE:KAV), the exploration company targeting the discovery of world-class mineral deposits in Botswana, is pleased to announce that it has conditionally raised £3,000,000 before expenses by the issue of 166,666,660 New Ordinary Shares in the capital of the Company (“New Ordinary Shares”) at a price per share of 1.8 pence. Fundraising The 158,555,555 New Ordinary Shares have […]

#POLB Poolbeg Pharma PLC – Upcoming Events

21 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, announces that its management and business development team will be attending and presenting at a number upcoming partnering and investor events from October 2022 to January 2023.   Partnering events • BIO-Europe from […]

October 2022 Investment Review – Alan Green talks to Ken Baksh

Former fund manager and market analyst Ken Baksh has over 30 years experience in the markets, and is widely respected for his insightful analysis and investing ideas. In the first of a series of monthly interviews with Alan Green, Ken offers his view on global economies before moving closer to home and asking whether the […]

#TEK Tekcapital Plc – Lucyd – Global Licensing Agreement Nautica Brand

Tekcapital Plc (AIM: TEK, OTCQB: TEKCF), the UK intellectual property investment group is pleased to announce Innovative Eyewear, Inc. (“Innovative Eyewear”) (NASDAQ: LUCY; LUCYW), a developer and retailer of cutting-edge smart eyewear and a subsidiary of portfolio company Lucyd Ltd, has licensed the global lifestyle brand Nautica® for smart eyewear.   “The Nautica smart eyewear line […]